A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048 · tracked via the Priya Life Science USA tracker

Sponsor

Sirt3 LLC

Phase

Not applicable

Started

2026-03-01

Last updated

2026-03-13

Condition(s) studied

Psoriasis

Investigational drug(s) / intervention(s)

Oral supplement containing 200mg Magnolia officinalis bark extractPlacebo

Oral supplement containing 200mg Magnolia officinalis bark extract: Viv is a consumer grade oral supplement containing 200mg Magnolia officinalis bark extract encapsulated in a hypromellose capsule.

Placebo: Oral hypromellose capsule with all inactive ingredients but lacking the Magnolia officinalis bark extract

Study summary

The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug).

Participants will:

* Take Viv or a placebo every day for 3 months.
* Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months.
* Be provided with at home blood collection kits, which they will use to collect blood at the beginning of the study and again at 1 months and 3 months.

Researchers will analyze these blood samples to measure the levels of specific inflammatory proteins and evaluate how they change over the course of the study in the participants taking Viv compared to those taking placebo.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Male of female, aged 18 years or older at time of consent. * Diagnosis of stable psoriasis affecting for at least 6 months confirmed by a dermatologist. * Patients with psoriasis-associated comorbidities including psoriatic arthritis are permitted, as long as those comorbidities are not severe enough to require treatment with systemic therapies as defined in the exclusion criteria. * Able to read and understand English. * Able to read, understand, and provide informed consent. * Able to use a personal smartphone device and download Chloe by People Science. * Able to receive shipment of the product at an address within the United States. * Able to adhere to study protocol (e.g., willing to collect and ship blood samples) Exclusion Criteria: Any potential participants who: * Do not have a personal smartphone, internet access, or unwilling to download Chloe. * Prior treatment with any systemic non-biologic immunosuppressive agents (e.g., methotrexate, cyclosporine, azathioprine) within 8 weeks prior to randomization. * Prior treatment with any systemic biologic therapies (e.g., guselkumab, risankizumab, ustekinumab, secukinumab, brodalumab, infliximab, adalimumab, golimumab, etanercept) within 6 months prior to randomization * Prior treatment with any other systemic investigational drugs within 6 months prior to randomization. * Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded: * Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding * Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes. * Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes. * Known hypersensitivity or previous allergic reaction to magnolia, rice or hypromellose. * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

Primary outcome measure(s)

Relative change in plasma Beta defensin 2 from baseline — From baseline to the end of study product/placebo use at 12 weeks
Change in plasma Beta defensin 2 levels between placebo and study product group at 4 weeks and 12 weeks relative to baseline as measured by ELISA

Trial sites (1)

Facility	City	Region	Status
Decentralized Study Coordinating Center	Englewood	New Jersey	Recruiting

Other trials for the same condition

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques Recruiting

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Active, not recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Active, not recruiting

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07471048 on ClinicalTrials.gov ↗ ← All trials in the USA